Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Clin Cancer Res. 2019 Sep 27;26(1):290–300. doi: 10.1158/1078-0432.CCR-19-1351

Figure 5. EZH2 is a repressor of antigen presentation by regulating the enrichment of H3K27me3 on the promoter regions of B2M.

Figure 5.

A. MOC1-esc1 cells were treated with GSK126 (10 μM), EPZ6438 (10 μM), or DMSO as control for 72 hours. H3K27me3 and EZH2 protein levels were determined by western blot. Total H3 was used as loading control. B. The mRNA expression levels of B2M, H2-K1, and CXCL10 were measured by qRT-PCR in MOC1-esc1 cells treated with EZH2 inhibitors and IFNγ. Relative mRNA levels were normalized to GAPDH. C, D. Chromatin immunoprecipitation (CHIP) for EZH2, H3K27me3, and IgG, and subsequent qPCR in B2M promoter using two independent primer sets. *P<0.05, **P<0.01, ***P<0.001. Significance was calculated by one-way ANOVA and Student’s t test. Data are shown as Mean± SD.